Vagus Nerve Stimulation for Anorexia
Trial Summary
What is the purpose of this trial?
This trial tests a device that sends electrical pulses to a nerve in the ear to help adolescents with eating disorders. The goal is to see if it can improve their eating behaviors by controlling hunger and fullness. Electrical stimulation of this nerve has been used in other treatments and has shown effects on weight.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Vagus Nerve Stimulation for Anorexia?
Research suggests that neuromodulation techniques, like vagus nerve stimulation, may help manage severe anorexia nervosa by targeting brain areas involved in the condition. While direct evidence for vagus nerve stimulation in anorexia is limited, similar treatments have shown potential in reducing symptoms by affecting brain activity.12345
Is transcutaneous auricular vagus nerve stimulation (taVNS) safe for humans?
How is the treatment taVNS different from other treatments for anorexia?
taVNS is unique because it is a non-invasive treatment that uses low-intensity electrical currents applied to the ear to stimulate the vagus nerve, which is involved in important body functions. Unlike other treatments, it does not require surgery and is portable, making it a safe and cost-effective option for managing symptoms of anorexia and related disorders.811121314
Research Team
Tom Hildebrandt
Principal Investigator
Icahn School of Medicine at Mount Sinai
Eligibility Criteria
This trial is for English-speaking teens aged 14-17 with low weight eating disorders, who are in a refeeding program and need to gain at least 8 lbs. It's not for those pregnant, with recent GI surgery, acute suicide risk, swallowing disorders, schizophrenia or bipolar disorder, certain device implants (like pacemakers), allergies to specific shake ingredients, substance misuse issues or diagnosed GI disturbances.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either vagal nerve stimulation or sham stimulation for 4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Sham (Device)
- taVNS (Device)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor
Dr. Brendan Carr
Icahn School of Medicine at Mount Sinai
Chief Executive Officer since 2024
MD, MA, MS
Dr. Vicki LoPachin
Icahn School of Medicine at Mount Sinai
Chief Medical Officer
MD, FACP, MBA